Adjuvant Composition for Local HPV Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for HPV infections, particularly in transformation zones like the cervix and anus, are invasive and ineffective for early-stage infections, leading to complications and the lack of therapeutic options for established infections, with existing vaccines being preventative and not addressing existing infections or all HPV strains.
Innovation Solution
A method involving the use of a composition comprising aluminium hydroxide and 3-deacylated monophospholipid A as an adjuvant to potentiate an immune response, directly applied to infected tissues within or adjacent to transformation zones, without the need for an immunogen, to treat and minimize HPV infection complications.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If invasive treatments are used for HPV infections, then severe infections can be treated, but early-stage infections cannot be effectively treated and complications arise
Solution Approach 1:
The patent changes the parameter of immune response activation from passive (vaccine prevention) to active (adjuvant-mediated local immune potentiation). By using aluminium hydroxide and 3-deacylated monophospholipid A as adjuvants, the treatment activates local immune cells to recognize and clear HPV infections at any stage, making the treatment effective for both early-stage and severe infections without requiring invasive procedures
Solution Approach 2:
The patent introduces adjuvants (aluminium hydroxide and 3-deacylated monophospholipid A) as intermediary substances that mediate between the infected tissue and the immune system. These adjuvants act as immunopotentiators that enhance local immune responses, enabling the body's own immune cells to effectively clear HPV infections without requiring invasive surgical intervention
2Reliability
If preventative vaccines are used, then future infections can be prevented, but existing infections are not addressed
Solution Approach 1:
The patent makes the adjuvant composition universally applicable for multiple functions: it can treat existing HPV infections of any type (broad-spectrum therapeutic action) while also potentially preventing reinfection. The composition works across different HPV strains without being limited to type-specific immunity, thereby expanding the versatility from purely preventative to therapeutically versatile
Solution Approach 2:
Instead of using vaccines that prevent infection before it occurs, the patent inverts the approach by using adjuvants that treat existing infections. The adjuvants work by potentiating local immune responses to clear established infections, reversing the traditional prevention-first paradigm to a treatment-capable approach
3Reliability
If type-specific vaccine immunity is used, then specific HPV strains are protected against, but all HPV strains are not covered
Solution Approach 1:
The adjuvant composition provides universal immune potentiation that is not limited to specific HPV strains. By enhancing local immune responses through adjuvant action, the treatment can recognize and clear various HPV strains (including types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 66, 68) without being constrained by type-specific immunity limitations
4Ease of operation
If no treatment is provided for early-stage infections, then invasive treatments are avoided, but complications and progression to severe stages occur
Solution Approach 1:
The patent applies adjuvants directly to infected tissues to create a preliminary local immune response before infections progress to severe stages. This preliminary immune activation prevents progression from early-stage to severe infections, eliminating the need for later invasive treatments while maintaining effective infection control
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach effectively reduces HPV infection complications, including cervical dysplasia and cancer, by enhancing the immune response locally, thereby clearing infections and preventing progression to severe stages without the need for invasive treatments or vaccine-specific immunity limitations.
Implementation Method 1
contacting the tissue with a therapeutically effective amount of a composition including a substance useful as an adjuvant for potentiating an immune response, the substance being comprised of a combination of aluminium hydroxide and 3-deacylated monophospholipid A
Data Source
AI summary
The invention relates to compositions including a substance useful as an adjuvant for potentiating an immune response, and methods of using the composition in individuals with infections of tissue within or adjacent to a transformation zone, such as the transformation zone of the cervix or anal canal.